Biomerica (Biomerica) EBIT : $-6.68 Mil (TTM As of Feb. 2024)

View and export this data going back to 1978. Start your Free Trial

What is Biomerica EBIT?

Biomerica's earnings before interest and taxes (EBIT) for the three months ended in Feb. 2024 was $-2.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2024 was $-6.68 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biomerica's annualized ROC % for the quarter that ended in Feb. 2024 was -199.13%. Biomerica's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -286.38%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biomerica's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -109.93%.

Biomerica EBIT Historical Data

The historical data trend for Biomerica's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica EBIT Chart

Biomerica Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

EBIT

Get a 7-Day Free Trial

-2.37

-2.67

-7.43

-4.53

-7.22

Biomerica Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EBIT	Get a 7-Day Free Trial															-1.65	-1.84	-1.23	-1.61	-2.00

Competitive Comparison of Biomerica's EBIT

For the Medical Devices subindustry, Biomerica's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomerica's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biomerica's EV-to-EBIT falls into.

Biomerica EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.68 Mil.

Biomerica (NAS:BMRA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biomerica's annualized ROC % for the quarter that ended in Feb. 2024 is calculated as:

	ROC % (Q: Feb. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Nov. 2023 )	+	Invested Capital (Q: Feb. 2024 ))	/ count )
=	-8 * ( 1 - -0.21% )	/	( (3.914	+	4.138)	/ 2 )
=	-8.0168	/	4.026
=	-199.13 %

where

	Invested Capital		(Q: Nov. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11.831	-	0.783	-	( 7.134	-	max(0, 1.822	-	10.265	+	7.134	))
=	3.914

	Invested Capital		(Q: Feb. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.342	-	0.885	-	( 5.319	-	max(0, 1.991	-	8.846	+	5.319	))
=	4.138

Note: The Operating Income data used here is four times the quarterly (Feb. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Biomerica's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Feb. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Nov. 2023		Q: Feb. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-8	/	( ( (1.101 + max(1.62, 0))	+	(1.011 + max(1.855, 0)) )	/	2 )
=	-8	/	( ( 2.721	+	2.866 )	/	2 )
=	-8	/	2.7935
=	-286.38 %

where Working Capital is:

	Working Capital		(Q: Nov. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.067	+	1.841	+	0.223)	-	(0.783	+	0.06	+	0.668)
=	1.62

	Working Capital		(Q: Feb. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.13	+	2.129	+	0.268)	-	(0.885	+	0.085	+	0.702)
=	1.855

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biomerica's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Feb. 2024 )
	=	-6.676	/	6.073
	=	-109.93 %

Biomerica EBIT Related Terms

Thank you for viewing the detailed overview of Biomerica's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomerica (Biomerica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

17571 Von Karman Avenue, Irvine, CA, USA, 92614

Website

https://www.biomerica.com

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.

Executives

John P. Kenny	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani	director, officer: Cheif Executive Officer	17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu	officer: Chief Financial Officer	12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri	director
Catherine Coste	director	966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi	director	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan	officer: Chief Financial Officer	114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano	director	11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio	officer: President-diagnostics	1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore	director, 10 percent owner, officer: Secretary	1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson	director	1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider	other: Greater than 5% holder	4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The	other: Greater than 5% holder	7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm	director	1533 MONROVIA AVE., NEWPORT BEACH CA 92663